Results 1 to 10 of about 1,535,618 (326)
Geographic atrophy: pathophysiology and current therapeutic strategies
Frontiers in Ophthalmology, 2023 Geographic atrophy (GA) is an advanced stage of age-related macular degeneration (AMD) that leads to gradual and permanent vision loss. GA is characterized by the loss of photoreceptor cells and retinal pigment epithelium (RPE), leading to distinct ...
Kalpana Rajanala +2 more
doaj +2 more sources
Geographic Atrophy in Age-Related Macular Degeneration
Ophthalmology Science, 2023 Purpose: To examine disease progression in age-related macular degeneration (AMD) at 2 distinct stages, progression to geographic atrophy (GA) versus GA expansion, by comparison of the risk and protective factors at each stage.
Tiarnan D.L. Keenan, BM BCh, PhD
doaj +2 more sources
Choroidal Round Hyporeflectivities in Geographic Atrophy. [PDF]
PLoS ONE, 2016 In geographic atrophy (GA), choroidal vessels typically appear on structural optical coherence tomography (OCT) as hyperreflective round areas with highly reflective borders.
Eleonora Corbelli +7 more
doaj +3 more sources
Imaging of Geographic Atrophy: A Practical Approach [PDF]
Ophthalmology and TherapyGeographic atrophy (GA) secondary to age-related macular degeneration is a chronic degenerative disease involving the retinal pigment epithelium, photoreceptors, and choriocapillaris leading to irreversible loss of visual function.
Gregor S. Reiter +4 more
doaj +2 more sources
Ophthalmology Science, 2023 Purpose: To examine the effectiveness of a targeted high-density microperimetry testing strategy for detecting visual sensitivity abnormalities in eyes with nascent geographic atrophy (nGA) when compared with standard central microperimetry testing ...
Zhichao Wu, BAppSc(Optom), PhD +2 more
doaj +2 more sources
Treating patients with geographic atrophy: are we there yet?
International Journal of Retina and Vitreous, 2023 Geographic atrophy (GA) is a progressive degenerative disease that significantly contributes to visual impairment in individuals aged 50 years and older. The development of GA is influenced by various modifiable and non-modifiable risk factors, including
Bani Antonio-Aguirre +1 more
doaj +2 more sources
Methodological Appraisal of Phase 3 Clinical Trials in Geographic Atrophy
Biomedicines, 2023 Geographic atrophy (GA) secondary to age-related macular degeneration is a common cause of blindness worldwide. Given the recent approval of the first therapy for GA, pegcetacoplan, we critically appraise methodological aspects of the phase 3 clinical ...
Marc Biarnés +8 more
doaj +2 more sources
Characterizing Patient Perceptions of Living with Geographic Atrophy: The Global Geographic Atrophy Insights Survey [PDF]
Clinical OphthalmologySophie J Bakri,1,* Christian K Brinkmann,2,* Amy Mulvey,3 Kathy Steinberg,3 Roz Katz,4 Pooja Vatsyayan,4 Sujata P Sarda,5 Nancy M Holekamp6 1Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA; 2Department of Ophthalmology, Dietrich ...
Bakri SJ +7 more
doaj +2 more sources
Scientific Reports, 2023 To compare clinical and imaging characteristics of extensive macular atrophy with pseudodrusen-like appearance (EMAP) versus diffuse-trickling geographic atrophy (DTGA) and non-diffuse-trickling geographic atrophy (nDTGA) phenotypes of age-related ...
Alessio Antropoli +7 more
doaj +2 more sources
Cells, 2023 Age-related macular degeneration (AMD) is the leading cause of vision loss and visual impairment in people over 50 years of age. In the current therapeutic landscape, intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies have been ...
Grace A. Borchert +7 more
doaj +2 more sources